The Greater Cannabis Company, Inc. Announces Collaboration with Renowned Cannabis Research Lab
March 16, 2021 at 01:12 pm
Share
Greater Cannabis Company announced a collaboration with Israel-based cannabis lab, Phytor LTD. Under this collaboration, the companies will develop and commercialize novel therapeutics for dermatological, chronic ailments and other conditions that have been notoriously difficult to treat using conventional therapies. The focus will be on cannabinoid and botanical-based wellness solutions, products and therapies that have consumer or commercial use cases. Phytor is led by Dr. Yehoshua Maor, a pharmacologist, toxicologist and cannabis expert who completed his graduate studies at the Hebrew University under the supervision of renowned professor, Dr. Raphael Mechoulam, one of the most acclaimed cannabis researchers, and known throughout the world as the “Father of Cannabis Research''. Dr. Maor’s research focused on both chemistry and biology of cannabinoids, which led him to gain immense knowledge in the bioactivity, pharmacokinetics and synthesis of cannabinoids, and an advanced understanding of their relevant therapeutic potential. As a graduate student he received awards for outstanding scientific presentations at the International Cannabis Research Society (ICRS). He was also a postdoctoral fellow of experimental medicine at the Harvard Institutes of Medicine before accepting a lead position at the Hebrew University Center of Excellence in Agriculture and Environmental Health. Under his direction, Phytor has become a world renowned cannabis R&D facility with an established team of multidisciplinary PhDs skilled in advanced science and research of pharmacological, agricultural and genetic characteristics of cannabinoids.
The Greater Cannabis Company, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of cannabinoid therapeutics. The Company conducts medical research, and is pursuing clinical trials, to develop cannabis-based treatments for various medical conditions and their symptoms with an initial focus on neuropsychiatric disorders. The Company conducts clinical studies on and commercialize the cannabinoid-based therapeutic and concentrate on cannabis related investment and development opportunities through direct equity investments, joint ventures, licensing agreements or acquisitions. Its delivery technologies use a bio-adhesive, adjustable dose, and fully dissolvable, non-irritant patch, which provides needle free, intra-oral systemic drug delivery.